This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Diabetes, Metabolic Syndrome And Cardiovascular Disease

Figure 5.3: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2010 89

Figure 5.4: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2010 90

Figure 5.5: Sales Forecast for the Global Diabetes Drug Market, 2008-2016 91

Figure 5.6: Sales Forecast for the U.S. Diabetes Drug Market, 2008-2016 92

Figure 6.1: Global Sales of Lantus, 2005-2011 104

Figure 6.2: Insulin Pump Market Share, 2011 141


Table 2.1: Top Ten Countries with the Largest Estimated Number of Diabetics (20 to 79 Years Age Group), 2012 and 2030 17

Table 2.2: U.S. Population of Diabetics (Diagnosed and Undiagnosed) Aged 20 Years or Older, 2010 19

Table 2.3: Cost of Diagnosed Diabetes in the U.S., 2007 21

Table 2.4: Medical Care Costs Attributable to Diabetes in the U.S., 2010 22

Table 2.5: Healthcare Utilization by Diabetic Patients 22

Table 2.6: Annual Cost of Care of UnitedHealthcare Adult Members with Diabetes, 2009 23

Table 2.7: Per-Event Costs of Diabetes Complications 24

Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome 28

Table 3.2: American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome 28

Table 3.3: Additional Metabolic Criteria for Research 30

Table 3.4: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S. 37

Table 3.5: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes 39

Table 3.6: Prevalence of Complications Among Patients with Diabetes 39

Table 3.7: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus 39

Table 3.8: Major Causes of End-Stage Renal Disease 39

Table 3.9: Clinical Recommendations for Adults with Diabetes 40

Table 3.10: Laboratory Assessment of Diabetic Vascular Disease 40

Table 3.11: Average Years Gained Free of Diabetes-related Disease with Intensive Management 41

Table 3.12: Summary of Cardiovascular Diseases (CVDs) 41

6 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs